Background and aims: Thismulticentertrialcomparedimmediate-releasetacrolimus
Tacrolimus is an important component of immunosuppressive regimens after solid organ transplantation. 3 In an annual transplant registry report in 2012, 96% of pediatric liver transplant recipients received tacrolimus as part of their initial immunosuppressive regimen, while 89%, 47%, and 1% received steroids, mycophenolate, and mammalian target of rapamycin inhibitors, respectively. 4 Currently available tacrolimus formulations include once-daily, prolongedreleaseandtwice-daily,immediate-releasetacrolimuscapsules, 5, 6 as wellasimmediate-releasetacrolimusgranulesfororalsuspension. 7 Althoughtheprolonged-andimmediate-releasetacrolimuscapsule formulations have shown similar efficacy and safety profiles, [8] [9] [10] the prolonged-release formulation has been associated with reduced intra-patient variability (IPV) in tacrolimus exposure and improved adherence to treatment in adults, 11, 12 whichcanimprovelong-term transplant outcomes. 13 HighIPVintacrolimustroughlevelshasbeenlinkedtoadverse transplant outcomes, 14 andisasignificantriskfactorforpoorlongterm graft survival in pediatric solid organ transplant patients. 15 A studyofmorethan6600kidneytransplantpatientswithafunction-inggraftatleast3yearspost-transplantationalsoshowedthatgraft survivalwassignificantlyreducedwithhigherIPV. 16 ImpactofIPV ongraftsurvivalwasparticularlystronginadolescents12-17years of age. Covariates that may influence variability in tacrolimus expo-sureinpediatricpatientsincludecytochromeP450-relatedgenetic polymorphisms, bodyweight, and hematocrit level. 17, 18 In addition, behavioral factors, such as nonadherence to treatment, particularly during adolescence when patients transition into adult care, 2 is also associated with poor graft and survival outcomes. 19 Indeed, nonadherence to immunosuppressive treatment was reported in 17%-53%ofadolescentsfollowinglivertransplantation. 20 Ameta-analysisincluding12studiesofadolescentkidney,liver,heart,and lung transplant recipients reported that 7.1% of patients did not adheretomedicationcomparedwithameta-analysisoffourstudies in younger children which reported a nonadherence rate of only 2.4%. 21 As such, it has been suggested that a focus on reducing nonadherencecouldminimizeriskduringthetransitionprocessto adulthood. 1, 22 Immediate-release tacrolimus is approved for use in pediatric kidney,liver,andheartallograftrecipients,andseveralsmallstudieshavedemonstratedgoodefficacyandtolerabilityofimmediaterelease tacrolimus in pediatric kidney 23 and liver transplant recipients. [24] [25] [26] However, prolonged-release tacrolimus is not widely approved in pediatric recipients and clinical experience in de novo pediatric transplantation is limited. We have previously reported the results of a pharmacokinetic analysis from a multicenter, randomized,open-label,Phase2,4-weektrialconductedinalargecohortof denovopediatrickidney,liver,andhearttransplantrecipients. 27 A similar linear relationship between tacrolimus exposure and trough levelswasobservedwithbothimmediate-releaseandprolonged-release formulations. 27 In the present paper, we report the results of a1-yearfollow-upstudyinthesamecohortofpatients,undertaken to evaluate the efficacy and safety of immediate-vs prolongedrelease tacrolimus. Thefirstpartofthestudywasa4-weekPKassessmentwhichhas been previously reported. 27 In the second part of the study (the focus of the present paper), patients continued to receive their randomized treatment for 48 additional weeks ( Figure 1 ). Concomitant basiliximab, thymoglobulin, mycophenolate mofetil, and/or steroids were prescribed according to routine clinical practice at each study center.
| MATERIAL AND ME THODS

| Study design and patients
| Treatment
Methylprednisolone or equivalent was given as a 300-600 mg/m 2 intravenous bolus pre, intra-, or postoperatively and at a dose of 60 mg/m 2 on the following day. Prednisolone or equivalent was administered at a daily dose of 40, 30, and 20 mg/m 2 on Days 2, 3, and 4, respectively, in kidney transplant patients; on Days 1, 2, and 3, respectively,inlivertransplantpatients;andonDays2-7,8-14,and 15-28,respectively,inhearttransplantpatients.Concomitantmedicationsknowntointeractwithtacrolimuswereprohibitedduringthe PKperiodbutwerepermittedduringthefollow-upperiod;however, no data on their effect on tacrolimus blood levels were collected. 
| Assessments
| Endpoints
The efficacy endpoints at Year 1 included the number of clinical acute rejections, BCAR episodes (including severity), patient and graft survival, and efficacy failure (a composite endpoint of death, graftloss,BCAR,orunknownoutcome). 
| Statistical analysis
| RE SULTS
| Study population
Of the 47 screened patients, 44 were enrolled and included in the FAS, of whom 24 and 20 patients were randomized to receive immediate-and prolonged-release tacrolimus, respectively ( Figure 2 ). Three patients prematurely discontinued the study in 
| Tacrolimus dose and whole blood trough levels
| Rejection episodes, graft and patient survival
Sevenpatientsreceivingimmediate-releasetacrolimusexperienced anacuterejectionepisode:twokidney,fourliver,andoneheartrecipient ( Table 2) 
| Efficacy failure
Composite efficacy failure occurred in eight (18.2%) patients, seven in the immediate-release and one in the prolonged-release tacrolimus group (Table 3) 
| Safety and tolerability
| Laboratory parameters
Therewerenoremarkablelaboratorytestresultsorvitalsignsobserved during the study; laboratory evaluations and vital signs were similarintheimmediate-andprolonged-releasetacrolimusgroups. 29, 30 The median age of the patients in our study was 11.0 (range: 4-15) years. Although tacrolimus clearance is known to be higher in patients aged <5 years, 31 patients nearly aged 5 years who were able to swallow intact capsules were included if they were considered old enough for tacrolimus clearance not to affect results.
In our de novo study population, seven (29.2%) patients receiving immediate-release tacrolimus experienced acute rejection, compared with two (10.0%) patients receiving prolonged-release tacrolimus. The number of acute rejections was too small to draw meaningful conclusions, and the study was not powered to examine results by organ class. Nevertheless, the low incidence of acute rejection in patients receiving prolonged-release tacrolimus is in line with previous 1-year post-transplant data in pediatric kidney transplant recipients, with acute rejection occurring in five (9.3%) andtwo(8.5%)patientsreceivingimmediate-releasetacrolimusand assigned to corticosteroid withdrawal and corticosteroid maintained treatment regimens, respectively. 32 In addition, in liver transplanted children, the incidence of acute rejections (about 40%) was in line witha1-yearstudyofpediatriclivertransplantrecipientswhichre-portedthatBCARoccurredin38(41.6%)patientspost-transplant. 28 Composite efficacy failure occurred in eight (18.2%) patients, the majority (seven) of whom received immediate-release tacrolimus. 29 In our study, an increase in blood creatinine as a drug-related TEAE was reported in 25% of patients receiving prolonged-release tacrolimus, all of whom were kidney transplant recipients. A similar incidence of increased creatinine (23.3%) has previously been reported 6 months after transplantation in pediatric kidneytransplantrecipients. 29 The patient numbers were too small to allow meaningful interpretation of the data; however, the fact that no liver transplant recipients in our study experienced increased blood creatinine is a promising result, considering that impaired renal function has been reported in pediatric patients postliver transplant, 33 andisamajorcauseofpost-transplantmorbidity. 4 These results suggest that neither formulation of tacrolimus was associated withrenalinsufficiencyoverthe1-yeartreatmentperiod.
All the results presented here must be considered within the context of the limitations of the study. The study was not powered for formal statistical analysis and all analyzes presented are descriptive. The once-daily tacrolimus formulation is not considered appropriate for younger children with faster clearance; therefore, the study preferentially targeted older children. In addition, only 20
(45.5%)ofourpatientswereadolescent,andgiventhatIPV,adherence to treatment, and subsequent outcomes, are a concern in this age group, 2 it would be of interest to investigate this patient population in further detail and to collect data on medication adherence. It would also be valuable in a future study to include patients from different racial groups (most children in the present study were White) and to perform genetic testing for the cytochrome-P450 enzymes CYP3A4 and CYP3A5 to determine whether participants are slow orfastmetabolizersoftacrolimus.Afurtherlimitationisthatbiopsies were read locally rather than centrally, and treatment was given according to local results, which might have influenced biopsy outcomes. However, pathomorphologic evaluation according to revised
Banff criteria was standardized across study centers in an attempt to mitigate potential variability between centers.
In conclusion, this is the first study to compare immediate-vs prolonged-releasetacrolimusinpediatricdenovokidney,liver,and heart allograft recipients. There was a low incidence of acute rejections and BCAR, the majority of which were mild/moderate in severity,andnodeathsorgraftlossesoccurredoverthe1-yearstudy period. Safety profiles were comparable between treatment groups and, importantly, no new safety signals were identified for either formulation in this pediatric population. The comparable PK profile of the tacrolimus formulations as well as the current data shows that over1-yearpost-transplant,prolonged-releasetacrolimus-basedimmunosuppression is effective and well tolerated in de novo pediatric solid organ transplant recipients.
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